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Abstract
Introduction: Microchimerism (MC) is the presence of a 
small amount of foreign cells or DNA within a person’s circu-
lation or tissues. It has been identified also in recipients of 
solid organ transplants where it seems to be critical for the 
development and maintenance of immunological tolerance. 
Nevertheless, natural and/or iatrogenic MC can be acquired 
prior to transplantation, through pregnancy and/or blood 
transfusion. Objective: The aim of this study was to detect 
the presence of MC in women after renal transplantation 
from male cadaveric donors and its relationship with graft 
outcomes. Methods: We studied by qPCR the presence of 
the DYS14 gene sequence of the Y chromosome in 12 fe-
males who received a kidney graft from a male donor before 
transplantation (T0), after 15 days (T1) and 1 year of trans-
plantation (T2). We found the sequence in all recipients after 
renal transplantation. Results: All the women were negative 
for this sequence prior to transplantation (T0). Mean (SD) Y-
related DNA quantity was 0.80 (0.69) ng/mL plasma and 0.15 
(0.26) ng/mL plasma at T1 and T2, respectively. No acute re-
jection was observed, and mean (SD) estimated Cr clearance 
was 68.8 (16.9) mL/min within 1 year from transplantation. 
Conclusions: Presence of MC was associated with good kid-
ney graft outcomes after 1 year of transplantation, but fur-
ther studies will be needed to investigate the relationship 
between clinical outcomes and the development of MC in 
renal transplant recipient. © 2020 S. Karger AG, Basel
Introduction
Microchimerism (MC) is defined as the presence of a 
small amount of foreign cells or DNA within a person’s 
circulation or tissues [1, 2] and can be acquired after a 
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showed that donor-derived DNA sequences could be de-
tected in the plasma of transplant recipients. This group 
further showed that different transplanted organs – for 
example, heart, liver and kidney – appeared to release dif-
ferent amounts of DNA into the circulation [3, 4]. The 
presence of small amount of foreign cell or DNA within 
a person’s circulation or tissue occurs at levels below 
those detectable by flow cytometry (<1%) that can be de-
tected by more sensitive methods such PCR is referred to 
as MC [5]. However, they have led to contrasting results 
since many different techniques and different control 
time points have been used to detect donor cells [6, 7]. It 
is fundamental to reach agreement about molecular MC 
detection techniques in order to assure comparability of 
results. In a longitudinal follow-up study of transplant 
recipients, the amount of MC was noted to have great 
variation in patients after different posttransplantation 
periods [8]. The role of MC in renal allograft adaption 
and rejection varies in different clinicopathological set-
tings and sex chromosomal MC in renal allograft [9]. The 
aim of the present study was to analyze cell-free DNA 
(cfDNA) circulating in the blood of renal transplant re-
cipients (RTRs) in order to evaluate the clinical impact of 
quantitative measurement of donor MC for possible tol-
erance mechanism purposes. Since cfDNA is released 
into the bloodstream mainly for cell death via apoptosis/
necrosis [10], we hypothesized that in female RTRs Y 
chromosome related circulating DNA can derive only 
from the male transplanted organ through the same 
mechanisms and therefore can be a marker of rejection. 
We assessed the frequency of MC in serial samples, before 
transplantation and after 15 days. We examined its influ-
ence on clinical course over a 12-month follow-up period 
and whether the presence of MC can be related to signs 
of rejection. The pretransplant blood sample is an impor-
tant control; it means that women were negative for cir-
culating male DNA in their plasma from a prior male 
pregnancy.
Materials and Methods
From July 2012 to June 2016, 127 patients (79 males, 48 fe-
males) underwent cadaveric renal transplantation in our Institu-
tion; cohort details are reported in Table 1. Out of the 48 females 
RTRs, 25 patients received a kidney graft from a male donor. 
Patients with a previous renal transplant and with lost data at 
follow-up were excluded. Twelve patients entered in the study 
and were prospectively evaluated. All subjects gave informed 
consent; the study had the approval by the institutional review 
board and followed the Declaration of Helsinki. They all under-
went their first renal transplantation from a cadaveric male do-
nor.
All patients received induction therapy (basiliximab) and were 
on immunosuppressive therapy based on triple drug association, 
according to our protocol. Immunosuppression included induc-
tion with the anti-CD25 monoclonal antibody basiliximab and a 
triple therapy with cyclosporine (CyA), methylprednisolone (CS), 
and EVR (Certican) or alternatively a triple therapy with CyA, CS, 
and MPA (Myfortic).
Nine RTRs received maintenance immunosuppressive therapy 
based on CyA, CS, and MPA. CyA was started at 6 mg/kg/day in 2 
separated doses, targeting whole blood was through levels of 150–
300 ng/mL until month 6 after Tx and 70–150 ng/mL thereafter. 
MPA was administered 1.44 g/day in 2 divided doses (group with 
CyA, MPA, and CS). The standard of care was a renal biopsy for 
graft dysfunction, which was defined as a >20% increase in serum 
Cr levels.
RTRs were prospectively studied by using a qPCR method for 
MC observation in plasma cfDNA based on the detection of the 
DYS14 gene sequences on the Y chromosome. The presence of Y-
related DNA sequences can be considered as a cell death marker 
released from necrotic or apoptotic cells in the transplanted organ 
or donor-derived hemopoietic cells in the recipient’s blood or oth-
er organs. Persistence of donor DNA in recipient plasma samples 
was assessed at 15 days (T1) and 12 months after transplantation 
(T2). A pretransplant blood sample was collected from each pa-
tient to serve as an individual control (T0). Moreover, we collected 
data on graft loss, renal function (serum Cr and eClC according to 
Cockroft Gault formula [11, 12]) and the occurrence of acute rejec-
tion.
DNA Extraction and Quantification of Total cfDNA
Peripheral blood was collected in an EDTA tube, transported 
within 1 h to the laboratory and centrifuged twice at 4°C for 10 min 
(1,600 and 14,000 rcf), in order to avoid contaminating DNA de-
riving from WBCs [13], according to the recently published guide-
lines from the Biological Stain Commission [14]. Plasma aliquots 
were stored at −80°C before use. DNA was extracted from 500 μL 
of plasma, using the QIAamp DSP Virus Kit (Qiagen, Italy) and 
RNAse digestion to prevent RNA interference during assay reac-
tion.
Table 1. Demographic and medical data of RTRs (from July 2012 
to June 2016)
Total RTRs, n 127
Males, n (%) 79 (62.2)
Females, n (%) 48 (37.8)
Mean follow-up period (SD), years 2.8 (1.04)
Mean (SD) male age at transplantation, years 55 (13.2)
Mean (SD) female age at transplantation, years 54 (13.3)
Underlying disease IN, NA, CGN, 
and ADPKD
RTRs, renal transplant recipients; SD, standard deviation; IN, 
interstitial nephropathy; NA, nephroangiosclerosis; CGN, chronic 




















   
   
   
   
   
   
   
   
   
   
   

























To verify the success of the DNA extraction procedure, we eval-
uated the total quantity of cell-free circulating DNA (cfDNA) by a 
qPCR method based on the detection of the single-copy gene APP 
(Amyloid Precursor protein, chr. 21q21.2, accession NM_000484), 
as reported in a previously published study by Lehmann et al. [15]. 
With this assay, we detect the total amount of circulating DNA in 
the blood of the RTR.
qPCR to Quantify Donor-Deriving cfDNA
The qPCR assay for donor-deriving cfDNA was performed 
as previously reported by Lambert et al. [16], choosing DYS14 
(Gene Bank sequence accession number, X06325) as a Y chro-
mosome-specific target sequence. The DYS14 sequence was se-
lected since it is a strictly Y-specific sequence and it is a multiple-
copy gene, thus allowing a very sensitive detection of Y-related 
cfDNA. Each sample was measured in duplicate and the mean 
quantity of each duplicate was expressed as ng per milliliter of 
plasma.
Results
The 12 female patients had no Y-related DNA in pre-
transplant samples (T0). Donor-specific DNA sequences 
were present in the plasma of all patients at T1 after kid-
ney transplantation. The mean (SD) plasma Y-related 
DNA quantity at this time was 0.80 (0.69) ng/mL plasma 
(median = 0.3, range 0–3.3) corresponding to a mean 
(SD) of 121.8 (104.8) genome equivalents/mL plasma 
(median = 45.5, range 0–494). A 5-fold decrease was evi-
denced in mean (SD) plasma Y-related DNA quantity at 
T2 after transplantation, which was 0.15 (0.26) ng/mL 
plasma (median = 0.04 range 0–0.73), corresponding to 
23.1 ± 40.0 genome equivalents/mL plasma (median = 
6.1, range 0–111). It is worth noting that most of the pa-
tients under study (80%) had levels of donor DNA below 
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Table 2. Demographic, clinical, and laboratory parameters of patients enrolled
Parameter(s) Value(s)
Age at transplantation, mean (SD), years 52.7 (10.9)
Median (range) dialytic time, months 24 (0–180)
Immunosuppressive therapy CyA, CS, and MPA/EVR
Serum Cr at 1 year, mean (SD), mg/dL 1.13 (0.35)
Clearance Cr/24 h at 1 year, mean (SD), mL/min 68.8 (16.9)
Blood transfusion before transplant, median (range), units 2 (0–10)
Mean (SD) DNA at 15 days, ng/mL – genome equivalents/mL (SD) 0.80 (0.69)–121.8(104.8)
Mean (SD) DNA at 1 year, ng/mL – genome equivalents/mL (SD) 0.15 (0.26)–23.1 (40.0)
SD, standard deviation.
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10 genome equivalents/mL plasma after 1 year from the 
intervention. After 1 year from transplantation, all the pa-
tients were compliant with follow-up. We observed no 
graft loss or acute rejection. Mean (SD) serum Cr levels 
were 1.13 (0.35) mg/dL and mean (SD) e-ClCr was 68.8 
(16.9) mL/min. No kidney biopsies from the 12 RTRs are 
available. No biopsies were available obviously due to the 
fact that Cr levels did not increase >20%, just as a sign for 
potential correlation to renal function. The values of clin-
ical and laboratory parameters of patients enrolled are 
shown in Table 2. Figure 1 reports mean plasma Y-related 
DNA quantity at T1 and T2 together with serum Cr levels 
and e-ClCr at T2.
Mean Y-related DNA quantity at T1 was not significant-
ly different between the non-blood-transfused versus 
blood-transfused recipient (0.74 ± 1.04 vs. 0.64 ± 0.67 ng/
mL) nor between patients with male offspring versus pa-
tients with no male offspring (0.58 ± 0.86 vs. 0.41 ± 0.41 ng/
mL). Patients’ baseline characteristics are listed in Table 3.
Discussion/Conclusion
MC has grown into a frequently discussed concept, es-
pecially in relation to transplantation. Important issues 
are how MC is induced, for instance, by damage caused 
by rejection and whether it may enhance recipient toler-
ance or whether it contributes to or is a sign of the devel-
opment of chronic irreversible lesions in grafts [17–22]. 
The consequences of MC are not well understood and are 
controversial. In transplantation studies, efforts should 
be made to verify the source of chimeric cell present in 
the recipients, because these sources may be various, 
since positive cells may derive from pregnancies and/or 
blood transfusion [1, 2]. MC baseline levels, meaning the 
amount of background chimerism already present before 
transplantation, were always investigated in our patients 
to distinguish between “background chimerism” and 
“transplantation induced MC.” The pretransplant blood 
sample (T0) tested for Y chromosome amplification is an 
important control as it means that women were negative 
for circulating male DNA in their plasma from a prior 
male pregnancy. Therefore, natural MC and iatrogenic 
MC could not be mistaken. Indeed, generally circulating 
male MC arising from pregnancy disappears from plasma 
post-delivery although MC can be maintained at the cel-
lular level. Therefore, if women do not have any circulat-
ing male DNA prior to transplantation and have low 
quantities posttransplantation, we could assume, with 
low chances to be wrong, that male DNA observed at T1 
and T2 is from the donor [2, 23].
Another strong point is that MC detection and quantifi-
cation by a qPCR method is an accurate and sensitive tech-
nique for the measurement of low-level nucleic acid mark-
ers. In addition, the DYS14 sequence was selected as a strict-
ly Y-specific multiple-copy gene which allows the 
achievement of higher sensitivity than single-copy genes, 
such as the SRY [16]. We observed the presence of donor-
specific DNA sequences in the plasma of all patients after 
15 days from kidney transplant. Since the DYS14 sequence 



















1 HD 39 2 0 0 23 0 0 55
2 HD 38 3 0 0 25, 27 0 1 54
3 PR 58 10 0 0 30 0 1 53
4 HD 70 1 0 0 0 0 0 12
5 HD 56 0 0 10 20, 25 0 0 36
6 PD 52 3 0 0 16, 20, 32 0 2 43
7 PD 34 2 0 0 20 0 0 37
8 HD 51 0 0 0 29 0 1 49
9 HD 60 9 0 7 0 0 0 44
10 PR 59 0 0 0 25 1 1 15
11 HD 63 5 0 12 25 0 0 12
12 PD 52 0 0 0 31 0 0 38




















   
   
   
   
   
   
   
   
   
   
   

























was negative at T0, the development of MC was certainly 
related to the graft and not to previous transfusion or preg-
nancies. A marked decrease in plasma DNA donor concen-
tration was recorded after 1 year from transplantation.
The occurrence of MC was associated with good graft 
outcomes in all our patients since none developed acute 
rejection or graft dysfunction in the observation period. 
Our results are in line with other positive experiences ob-
served in the literature [24, 25]. However, the presence of 
MC in the long term and its effects on graft outcomes 
should be clarified in studies with longer follow-up. Some 
limitations of our study have to be acknowledged.
The limited number of patients investigated prevents 
us from reaching definitive conclusions. The technique 
used to determine the presence of MC (DYS14 assay) is 
restricted to the detection of male donor MC in a female 
recipient. Gender-independent analysis of MC requires 
more expensive, sophisticated, and time-consuming ap-
proaches requiring genotyping the donor and recipient to 
establish a unique donor “genetic fingerprint” [26] or ge-
nome-wide methylation sequencing [27].
Detection of donor-specific DNA in the plasma of re-
cipient patients has been previously reported by Dennis 
Lo et al. [3] even in cases with no cellular chimerism in 
the recipients’ blood. The origin of plasma DNA chime-
rism in these patients could derive from the transplanted 
organ or donors’ hemopoietic cells residing in tissues [3]. 
On this basis, we concentrated on cfDNA analysis.
No kidney biopsies were available from the 12 patients, 
with supporting findings related to functional graft. On 
the other hand, our intent was the development of a min-
imally invasive approach based just on serial peripheral 
blood draws for transplantation monitoring.
Our data show good kidney graft outcomes associated 
with the presence of MC after 1 year of transplantation. 
However, our analysis does not allow us to study the dy-
namic of MC in recipients manifesting acute rejection. 
Therefore, further studies will be needed to investigate 
the relationship between clinical outcomes and the devel-
opment of MC in RTR.
There are some limitations to our study that must be 
acknowledged. We recognized the inherent weaknesses 
of any single study. The relatively low patient number 
would affect the power of the study to elucidate our study. 
Actually, the significance of MC after transplantation is 
not clear. With our data, it is hard to see if there is an im-
pact of the transplantation outcome, and further investi-
gations on these cases and for longer times (5, 10, and 15 
years) are needed.
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